Pharmaceutical Care of a Patient with Platinum-Resistant Recurrent Ovarian Cancer Treated by Platinum-Based Chemotherapy Regimen
Objective To investigate the selection of chemotherapy regimens for patients with platinum-resistant recurrent ovarian cancer.Methods The treatment process of a patient with platinum-resistant recurrent ovarian cancer admitted to the Fuling Hospital of Chongqing University was retrospectively analyzed.The clinical physicians formulated a chemotherapy regimen consisting of Paclitaxel for Injection(Albumin Bound)+oxaliplatin.However,during the pharmaceutical consultation,the clinical pharmacists inquired about the patient´s medical history and found that she had experienced numbness in the hands and feet after the last two rounds of chemotherapy,with occasional needle-like sensations,and the symptoms gradually worsened.Based on the patient´s medication history,relevant guidelines,clinical evidence-based evidence,it was considered that the above adverse drug reactions(ADRs)were the neurotoxic reactions induced by paclitaxel according to the occurrence time of ADRs.Due to the strong neurotoxicity of oxaliplatin,the clinical pharmacists suggested adjusting the chemotherapy regimen to paclitaxel liposomes+carboplatin after discussion with physicians-in-charge.Results The physicians adopted the suggestions.The patient´s vital signs remained stable during chemotherapy,and there was no obvious neurotoxic reaction such as numbness in the hands or feet;re-examinations of electrolytes,liver and kidney function,blood routine showed no abnormality.Conclusion Clinical pharmacists´ participation in the selection of platinum-based chemotherapy regimens for patients with platinum-resistant recurrent ovarian cancer can provide individualized medication regimens,ensure the safety and effectiveness of medication,and provide a reference for the treatment and management of similar patients.